Gastrointestinal (GI) cancer (CA) drugs approved by the US Food and Drug Administration (FDA): Clinical value and cost considerations.

被引：0
|
作者：
Jiang, Di Maria
Jang, Raymond Woo-Jun
Chan, Kelvin K.
Liu, Geoffrey
Amir, Eitan
Elimova, Elena
机构：
[1] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
[2] Princess Margaret Canc Ctr, Toronto, ON, Canada
[3] Univ Toronto, Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada
[4] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[5] Princess Margaret Canc Ctr, Dept Med Oncol, Toronto, ON, Canada
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.6619
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6619
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration
    Molto, Consolacion
    Hwang, Thomas J.
    Borrell, Maria
    Andres, Marta
    Gich, Ignasi
    Barnadas, Agusti
    Amir, Eitan
    Kesselheim, Aaron S.
    Tibau, Ariadna
    CANCER, 2020, 126 (19) : 4390 - 4399
  • [2] Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
    Tibau, Ariadna
    Molto, Consolacion
    Ocana, Alberto
    Templeton, Arnoud J.
    Del Carpio, Luis P.
    Del Paggio, Joseph C.
    Barnadas, Agusti
    Booth, Christopher M.
    Amir, Eitan
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (05): : 486 - 492
  • [3] Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations
    Jiang, Di Maria
    Chan, Kelvin K. W.
    Jang, Raymond W.
    Booth, Christopher
    Liu, Geoffrey
    Amir, Eitan
    Mason, Robert
    Everest, Louis
    Elimova, Elena
    CANCER MEDICINE, 2019, 8 (04): : 1584 - 1593
  • [4] RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration
    Cherny, Nathan I.
    Dafni, Urani
    Bogaerts, Jan
    Latino, Nicola J.
    Pentheroudakis, George
    Douillard, Jean-Yves
    Tabernero, Josep
    Zielinski, Christoph
    Piccart, Martine J.
    de Vries, Elisabeth G. E.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (10):
  • [5] RE: Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Response
    Tibau, Ariadna
    Molto, Consolacion
    Amir, Eitan
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2018, 110 (10):
  • [6] Magnitude of clinical benefit of cancer drugs approved based on single-arm trials (SAT) by the US Food and Drug Administration (FDA)
    Molto Valiente, C.
    Borrell, M.
    Ocana Fernandez, A.
    Templeton, A. J.
    del Carpio, L. P.
    Del Paggio, J.
    Barnadas, A.
    Booth, C. M.
    Tibau, A.
    Amir, E.
    ANNALS OF ONCOLOGY, 2018, 29 : 564 - 564
  • [7] Clinical benefit and cost of breakthrough cancer drugs approved by the US Food and Drug Administration (vol 126, pg 4390, 2020)
    Molto, Consolacion
    Hwang, Thomas J.
    Borrell, Maria
    Andres, Marta
    Gich, Ignasi
    Barnadas, Agusti
    Amir, Eitan
    Kesselheim, Aaron S.
    Tibau, Ariadna
    CANCER, 2021, 127 (17) : 3266 - 3266
  • [8] DRUGS APPROVED FOR CLINICAL USE BY FOOD AND DRUG ADMINISTRATION
    DEHAEN, P
    JOURNAL OF NEW DRUGS, 1965, 5 (06): : 358 - &
  • [9] DRUGS APPROVED FOR CLINICAL USE BY FOOD AND DRUG ADMINISTRATION
    DEHAEN, P
    JOURNAL OF NEW DRUGS, 1966, 6 (02): : 112 - &
  • [10] A Survey of Survival Outcomes for Targeted Cancer Drugs Approved by the US Food and Drug Administration
    He, Qian
    Li, Qiu
    Lv, Fanzhen
    Kaitin, Kenneth I.
    Shao, Liming
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2021, 55 (04) : 676 - 684
12345